These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Hamada K, Tomita Y, Inoue A, Fujimoto T, Hashimoto N, Myoui A, Yoshikawa H, Hatazawa J. Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843 [Abstract] [Full Text] [Related]
4. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT. Byun BH, Kim SH, Lim SM, Lim I, Kong CB, Song WS, Cho WH, Jeon DG, Lee SY, Koh JS, Chung SK. Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716 [Abstract] [Full Text] [Related]
6. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor. Qin Z, Tang Y, Wang H, Cai W, Fu H, Li J, Ma C. J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587 [Abstract] [Full Text] [Related]
8. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Hawkins DS, Rajendran JG, Conrad EU, Bruckner JD, Eary JF. Cancer; 2002 Jun 15; 94(12):3277-84. PubMed ID: 12115361 [Abstract] [Full Text] [Related]
9. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis. Hongtao L, Hui Z, Bingshun W, Xiaojin W, Zhiyu W, Shuier Z, Aina H, Yuanjue S, Daliu M, Zan S, Yang Y. Surg Oncol; 2012 Dec 15; 21(4):e165-70. PubMed ID: 22884956 [Abstract] [Full Text] [Related]
11. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET. Ye Z, Zhu J, Tian M, Zhang H, Zhan H, Zhao C, Yang D, Li W, Lin N. Ann Nucl Med; 2008 Jul 15; 22(6):475-80. PubMed ID: 18670853 [Abstract] [Full Text] [Related]
12. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI. Byun BH, Kong CB, Lim I, Kim BI, Choi CW, Song WS, Cho WH, Jeon DG, Koh JS, Lee SY, Lim SM. Eur J Nucl Med Mol Imaging; 2014 Aug 15; 41(8):1553-62. PubMed ID: 24652233 [Abstract] [Full Text] [Related]
15. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma. Lee I, Byun BH, Lim I, Kim BI, Kong CB, Song WS, Cho WH, Koh JS, Lim SM. Medicine (Baltimore); 2018 Sep 15; 97(37):e12318. PubMed ID: 30212975 [Abstract] [Full Text] [Related]
17. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment? Frezza AM, Beale T, Bomanji J, Jay A, Kalavrezos N, Dileo P, Whelan J, Strauss SJ. BMC Cancer; 2014 Jan 15; 14():23. PubMed ID: 24422949 [Abstract] [Full Text] [Related]
18. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model. Dutour A, Decouvelaere AV, Monteil J, Duclos ME, Roualdes O, Rousseau R, Marec-Bérard P. J Nucl Med; 2009 Sep 15; 50(9):1533-40. PubMed ID: 19690032 [Abstract] [Full Text] [Related]